Managing IP has been instrumental in the company’s strategy. Together with the worldwide regulatory strategy, they are crucial elements for any biotech startup. Please check out how it went in White Paper done jointly with our IP partner - Seventh.ai.
Here are the results:
Agile IP process enabled A.D.A.M. to iterate on the IP as a natural evolution of the R&D process;
Investors in due diligence can now review the innovations that are core to the business;
We know better where our differentiators lie;
As we are building the culture of innovation, our internal processes became better organized around the innovation development;